Non-steroidal anti-inflammatory drugs and cancer risk in women: Results from the Women's Health Initiative

International Journal of Cancer

Volumn 135, Issue 8, 2014, Pages 1869-1883

  Brasky, Theodore M ^a,b   Liu, Jingmin ^b   White, Emily ^b,c   Peters, Ulrike ^b   Potter, John D ^b,d   Walter, Roland B ^b,c   Baik, Christina S ^b   Lane, Dorothy S ^e   Manson, Joann E ^f   Vitolins, Mara Z ^g   Allison, Matthew A ^h   Tang, Jean Y ⁱ   Wactawski Wende, Jean ^j  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b USA   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d MASSEY UNIVERSITY   (New Zealand)

^e STONY BROOK UNIVERSITY   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

^g WAKE FOREST SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j UNIVERSITY AT BUFFALO   (United States)

more..

Author keywords

aspirin; cancer; ibuprofen; inflammation; naproxen; non steroidal anti inflammatory drug

Indexed keywords

ACETYLSALICYLIC ACID; IBUPROFEN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; ARTICLE; BLADDER CANCER; BREAST CANCER; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; DISEASE ASSOCIATION; DRUG EXPOSURE; DRUG USE; ENDOMETRIUM CANCER; FEMALE; FOLLOW UP; GENITAL TRACT CANCER; HEMATOLOGIC MALIGNANCY; HUMAN; KIDNEY CANCER; LOW DRUG DOSE; LUNG CANCER; MAJOR CLINICAL STUDY; MELANOMA; OBSERVATIONAL STUDY; OVARY CANCER; PANCREAS CANCER; PATIENT SELECTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK REDUCTION; THYROID CANCER; TREATMENT DURATION; UNITED STATES; URINARY TRACT CANCER; WOMEN'S HEALTH;

ASPIRIN; CANCER; IBUPROFEN; INFLAMMATION; NAPROXEN; NON-STEROIDAL ANTI-INFLAMMATORY DRUG;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICARCINOGENIC AGENTS; ASPIRIN; FEMALE; HUMANS; IBUPROFEN; INCIDENCE; MIDDLE AGED; NAPROXEN; NEOPLASMS; POSTMENOPAUSE; PROSPECTIVE STUDIES; RISK;

EID: 84905722146     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28823     Document Type: Article

References (44)

1. Bosetti C, Rosato V, Gallus S, et al. Aspirin and cancer risk: a quantitative review to 2011. Ann Oncol 2012; 23: 1403-15.
2. Algra AM, Rothwell PM,. Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol 2012; 13: 518-27.
3. Rothwell PM, Fowkes FG, Belch JF, et al. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 2011; 377: 31-41.
4. Rothwell PM, Price JF, Fowkes FG, et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 2012; 379: 1602-12.
5. Rothwell PM, Wilson M, Price JF, et al. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet 2012; 379: 1591-601.
6. Cook NR, Lee IM, Gaziano JM, et al. Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA 2005; 294: 47-55.
7. Cook NR, Lee IM, Zhang SM, et al. Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial. Ann Intern Med 2013; 159: 77-85.
8. Bardia A, Ebbert JO, Vierkant RA, et al. Association of aspirin and nonaspirin nonsteroidal anti-inflammatory drugs with cancer incidence and mortality. J Natl Cancer Inst 2007; 99: 881-9.
9. Jacobs EJ, Thun MJ, Bain EB, et al. A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence. J Natl Cancer Inst 2007; 99: 608-15.
10. Brasky TM, Potter JD, Kristal AR, et al. Non-steroidal anti-inflammatory drugs and cancer incidence by sex in the VITamins And Lifestyle (VITAL) cohort. Cancer Causes Control 2012; 23: 431-44.
11. Friis S, Sorensen HT, McLaughlin JK, et al. A population-based cohort study of the risk of colorectal and other cancers among users of low-dose aspirin. Br J Cancer 2003; 88: 684-8.
12. Schreinemachers DM, Everson RB,. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 1994; 5: 138-46.
13. Sorensen HT, Friis S, Norgard B, et al. Risk of cancer in a large cohort of nonaspirin NSAID users: a population-based study. Br J Cancer 2003; 88: 1687-92.
14. Potter JD,. The failure of chemoprevention. World Cancer Report 2014. Lyon, France: IARC, 2014.
15. Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Control Clin Trials 1998; 19: 61-109.
16. Anderson GL, Manson J, Wallace R, et al. Implementation of the Women's Health Initiative study design. Ann Epidemiol 2003; 13: S5-S17.
17. Hays J, Hunt JR, Hubbell FA, et al. The Women's Health Initiative recruitment methods and results. Ann Epidemiol 2003; 13: S18-S77.
18. Stefanick ML, Cochrane BB, Hsia J, et al. The Women's Health Initiative postmenopausal hormone trials: overview and baseline characteristics of participants. Ann Epidemiol 2003; 13: S78-S86.
19. Ritenbaugh C, Patterson RE, Chlebowski RT, et al. The Women's Health Initiative Dietary Modification trial: overview and baseline characteristics of participants. Ann Epidemiol 2003; 13: S87-S97.
20. Jackson RD, LaCroix AZ, Cauley JA, et al. The Women's Health Initiative calcium-vitamin D trial: overview and baseline characteristics of participants. Ann Epidemiol 2003; 13: S98-S106.
21. Langer RD, White E, Lewis CE, et al. The Women's Health Initiative Observational Study: baseline characteristics of participants and reliability of baseline measures. Ann Epidemiol 2003; 13: S107-S121.
22. Curb JD, McTiernan A, Heckbert SR, et al. Outcomes ascertainment and adjudication methods in the Women's Health Initiative. Ann Epidemiol 2003; 13: S122-S128.
23. Pierce BL, Neuhouser ML, Wener MH, et al. Correlates of circulating C-reactive protein and serum amyloid A concentrations in breast cancer survivors. Breast Cancer Res Treat 2009; 114: 155-67.
24. Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. New Engl J Med 2004; 350: 1387-97.
25. Stannus OP, Jones G, Blizzard L, et al. Associations between serum levels of inflammatory markers and change in knee pain over 5 years in older adults: a prospective cohort study. Ann Rheum Dis 2013; 72: 535-40.
26. Bielecka-Dabrowa A, Goch JH, Mikhailidis DP, et al. The influence of atorvastatin on parameters of inflammation and function of the left ventricle in patients with dilated cardiomyopathy. Med Sci Monit 2009; 15: MS12-M23.
27. Allison M, Garland C, Chlebowski R, et al. The association between aspirin use and the incidence of colorectal cancer in women. Am J Epidemiol 2006; 164: 567-75.
28. Harris RE, Chlebowski RT, Jackson RD, et al. Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women's Health Initiative. Cancer Res 2003; 63: 6096-101.
29. Phipps AI, Anderson GL, Cochrane BB, et al. Migraine history, nonsteroidal anti-inflammatory drug use, and risk of postmenopausal endometrial cancer. Horm Cancer 2012; 3: 240-8.
30. Gamba CS, Swetter SM, Stefanick ML, et al. Aspirin is associated with lower melanoma risk among postmenopausal Caucasian women: the Women's Health Initiative. Cancer 2013; 119: 1562-9.
31. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations), Bethesda, MD: National Cancer Institute, 2012.
32. Wang D, Dubois RN,. The role of COX-2 in intestinal inflammation and colorectal cancer. Oncogene 2010; 29: 781-8.
33. Brueggemeier RW, Diaz-Cruz ES, Li P-K, et al. Translational studies on aromatase, cyclooxygenases, and enzyme inhibitors in breast cancer. J Steroid BiochemMol Biol 2005; 95: 129-36.
34. Gates MA, Tworoger SS, Eliassen AH, et al. Analgesic use and sex steroid hormone concentrations in postmenopausal women. Cancer Epidemiol Biomarkers Prev 2010; 19: 1033-41.
35. Rothwell PM, Wilson M, Elwin CE, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 2010; 376: 1741-50.
36. Cole BF, Logan RF, Halabi S, et al. Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. J Natl Cancer Inst 2009; 101: 256-66.
37. Chan AT, Giovannucci EL, Meyerhardt JA, et al. Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. JAMA 2005; 294: 914-23.
38. Chan AT, Ogino S, Fuchs CS,. Aspirin use and survival after diagnosis of colorectal cancer. JAMA 2009; 302: 649-58.
39. McCormack VA, Hung RJ, Brenner DR, et al. Aspirin and NSAID use and lung cancer risk: a pooled analysis in the International Lung Cancer Consortium (ILCCO). Cancer Causes Control 2011; 22: 1709-20.
40. Oh SW, Myung SK, Park JY, et al. Aspirin use and risk for lung cancer: a meta-analysis. Ann Oncol 2011; 22: 2456-65.
41. Baandrup L, Faber MT, Christensen J, et al. Nonsteroidal anti-inflammatory drugs and risk of ovarian cancer: systematic review and meta-analysis of observational studies. Acta Obstet Gynecol Scand 2013; 92: 245-55.
42. Neill AS, Nagle CM, Protani MM, et al. Aspirin, nonsteroidal anti-inflammatory drugs, paracetamol and risk of endometrial cancer: a case-control study, systematic review and meta-analysis. Int J Cancer 2013; 132: 1146-55.
43. Luo T, Yan HM, He P, et al. Aspirin use and breast cancer risk: a meta-analysis. Breast Cancer Res Treat 2012; 131: 581-7.
44. Li S, Liu Y, Zeng Z, et al. Association between non-steroidal anti-inflammatory drug use and melanoma risk: a meta-analysis of 13 studies. Cancer Causes Control 2013; 24: 1505-16.